Research indicates that stopping GLP-1 weight reduction medications, such as Mounjaro or Zepbound, could lead to weight gain, with some individuals regaining up to 12-15% of their initial weight
These may include injection site reactions, mild to moderate nausea, vomiting, diarrhea, constipation, abdominal pain, and decreased appetite
Its not used to treat diabetes, and you dont need to have a diabetes diagnosis to use it

WHAT KAISER REQUIRES FIRST Step Therapy Requirements Even in regions where Kaiser covers Zepbound, you must typically "fail" multiple other treatments first: Kaiser Northwest Example (Most Documented) To qualify for Zepbound coverage in Kaiser Northwest, you must demonstrate: [3] Kaiser Zepbound Coverage Criteria BMI 30 (obesity) OR BMI 27 with a comorbidity (hypertension, diabetes, high cholesterol) Age 18+ Following a structured diet and exercise program (documented, not just attested) Failed at least 2 prior weight loss medications : Phentermine Diethylpropion Qsymia (phentermine/topiramate) Contrave (naltrexone/bupropion) Tried semaglutide (Wegovy or Ozempic) for minimum 6 months and either: It was ineffective (didn't achieve target weight loss) Cannot tolerate due to allergy, serious side effects, or contraindication Continuation Requirements (To Keep Coverage) Initial approval typically for 12 months Must document at least 5% weight loss after starting tirzepatide to continue coverage Bariatric medicine chart review required before switching from semaglutide to Zepbound Kaiser's Internal "Medical Weight Management" Program Kaiser often requires patients to enroll in their internal weight management program before approving GLP-1s

C.GottesdienerK.FiedorekF